abstract |
The present invention relates to novel indoline derivatives which bind to the 5-HT2B receptor and are capable of interfering with the effects of 5-hydroxytryptamine (5-HT) at the 5-HT2B receptor; to processes for their preparation; to pharmaceutical compositions containing them; and to the use of such compounds in therapy. |